October 26, 2016
AbbVie’s Rova-T Wins ‘Most Promising Clinical Candidate’ Award
AbbVie’s Rova-T Wins ‘Most Promising Clinical Candidate’ Award award at World Antibody Drug Conjugate Summit.

The AbbVie Stemcentrx investigational asset known as “Rova-T” (rovalpituzumab tesirine) was recently recognized at the 7th Annual World Antibody Drug Conjugate (ADC) Awards as the “Most Promising Clinical Candidate” for fighting cancer tumors.

World ADC is considered the definitive forum for ADC thought leaders. The 7th Annual World ADC Summit gathered more than 650 colleagues and 90 ADC experts for 96 sessions on drug development, pre-clinical and clinical work and the latest intelligence in this area of oncology.

With the addition of Rova-T and additional early stage and pre-clinical assets, AbbVie’s oncology portfolio consists of marketed medicines and a robust pipeline of new molecules being evaluated worldwide in nearly 200 clinical trials in 20 different tumor types. 

AbbVie Stemcentrx also won the top prize at World ADC for “Best Publication,” and AbbVie Stemcentrx vice president and chief scientific officer Scott Dylla, Ph.D., was named runner-up for “Individual Input to the Field 2015/2016.”



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?